Boehringer Ingelheim and Cognizant announce the launch of a unified cloud platform to bring innovative therapies to patients faster
Cognizant (CTSH) and Boehringer Ingelheim have announced the successful launch of Phase One of their 'One Medicine Platform,' a unified cloud platform powered by Veeva Development Cloud. The new system replaces over 20 legacy platforms, streamlining medicinal development processes and enhancing operational efficiencies.
The platform, implemented by Cognizant as the prime system integrator in collaboration with Syneos Health Consulting and Veeva, unifies clinical data, operations, regulatory, and quality functions. The system is designed to serve 15,000+ users working in Clinical Development programs, addressing previous challenges of disconnected vendor systems and complex workflows.
Phase Two of the project will focus on enhancing Boehringer's clinical operations and integrating additional regulatory function modules. The implementation aims to resolve data challenges, reduce latencies, and accelerate the company's product go-to-market timeline.
Cognizant (CTSH) e Boehringer Ingelheim hanno annunciato il lancio di successo della Fase Uno della loro 'One Medicine Platform', una piattaforma cloud unificata alimentata da Veeva Development Cloud. Il nuovo sistema sostituisce oltre 20 piattaforme legacy, semplificando i processi di sviluppo dei medicinali e migliorando l'efficienza operativa.
La piattaforma, implementata da Cognizant come principale integratore di sistema in collaborazione con Syneos Health Consulting e Veeva, unifica dati clinici, operazioni, funzioni regolatorie e di qualità. Il sistema è progettato per servire oltre 15.000 utenti che lavorano in programmi di Sviluppo Clinico, affrontando le sfide precedenti dei sistemi dei fornitori disconnessi e dei flussi di lavoro complessi.
La Fase Due del progetto si concentrerà sul miglioramento delle operazioni cliniche di Boehringer e sull'integrazione di ulteriori moduli di funzioni regolatorie. L'implementazione mira a risolvere le sfide dei dati, ridurre le latenze e accelerare il tempo di immissione sul mercato dei prodotti dell'azienda.
Cognizant (CTSH) y Boehringer Ingelheim han anunciado el exitoso lanzamiento de la Fase Uno de su 'One Medicine Platform', una plataforma en la nube unificada impulsada por Veeva Development Cloud. El nuevo sistema reemplaza más de 20 plataformas heredadas, agilizando los procesos de desarrollo de medicamentos y mejorando la eficiencia operativa.
La plataforma, implementada por Cognizant como el principal integrador de sistemas en colaboración con Syneos Health Consulting y Veeva, unifica datos clínicos, operaciones, funciones regulatorias y de calidad. El sistema está diseñado para atender a más de 15,000 usuarios que trabajan en programas de Desarrollo Clínico, abordando los desafíos anteriores de sistemas de proveedores desconectados y flujos de trabajo complejos.
La Fase Dos del proyecto se centrará en mejorar las operaciones clínicas de Boehringer e integrar módulos adicionales de funciones regulatorias. La implementación tiene como objetivo resolver los desafíos de datos, reducir las latencias y acelerar el tiempo de lanzamiento al mercado de los productos de la empresa.
코그니전트 (CTSH)와 보에링거 인겔하임은 '원 메디슨 플랫폼'의 1단계 성공적인 출범을 발표했습니다. 이 통합 클라우드 플랫폼은 비바 개발 클라우드에 의해 구동됩니다. 새로운 시스템은 20개 이상의 기존 플랫폼을 대체하여 의약품 개발 프로세스를 간소화하고 운영 효율성을 향상시킵니다.
코그니전트가 시네오스 헬스 컨설팅 및 비바와 협력하여 주요 시스템 통합자로 구현한 이 플랫폼은 임상 데이터, 운영, 규제 및 품질 기능을 통합합니다. 이 시스템은 임상 개발 프로그램에서 일하는 15,000명 이상의 사용자를 지원하도록 설계되었으며, 이전의 연결되지 않은 공급업체 시스템과 복잡한 작업 흐름의 문제를 해결합니다.
프로젝트의 2단계는 보에링거의 임상 운영을 개선하고 추가 규제 기능 모듈을 통합하는 데 중점을 둘 것입니다. 구현은 데이터 문제를 해결하고 지연을 줄이며 회사의 제품 시장 출시 일정을 가속화하는 것을 목표로 합니다.
Cognizant (CTSH) et Boehringer Ingelheim ont annoncé le lancement réussi de la Phase Un de leur 'One Medicine Platform', une plateforme cloud unifiée alimentée par Veeva Development Cloud. Le nouveau système remplace plus de 20 plateformes héritées, rationalisant les processus de développement des médicaments et améliorant l'efficacité opérationnelle.
La plateforme, mise en œuvre par Cognizant en tant qu'intégrateur système principal en collaboration avec Syneos Health Consulting et Veeva, unifie les données cliniques, les opérations, les fonctions réglementaires et de qualité. Le système est conçu pour servir plus de 15 000 utilisateurs travaillant dans des programmes de Développement Clinique, répondant aux défis précédents des systèmes de fournisseurs déconnectés et des flux de travail complexes.
La Phase Deux du projet se concentrera sur l'amélioration des opérations cliniques de Boehringer et l'intégration de modules de fonctions réglementaires supplémentaires. L'implémentation vise à résoudre les problèmes de données, à réduire les latences et à accélérer le délai de mise sur le marché des produits de l'entreprise.
Cognizant (CTSH) und Boehringer Ingelheim haben den erfolgreichen Start der Phase Eins ihrer 'One Medicine Platform' bekannt gegeben, einer einheitlichen Cloud-Plattform, die von Veeva Development Cloud betrieben wird. Das neue System ersetzt über 20 veraltete Plattformen, optimiert die Prozesse in der Arzneimittelentwicklung und verbessert die Betriebseffizienz.
Die Plattform, die von Cognizant als Hauptsystemintegrator in Zusammenarbeit mit Syneos Health Consulting und Veeva implementiert wurde, vereint klinische Daten, Operationen, regulatorische und Qualitätsfunktionen. Das System ist darauf ausgelegt, über 15.000 Benutzer zu bedienen, die in klinischen Entwicklungsprogrammen arbeiten, und adressiert frühere Herausforderungen durch getrennte Anbietersysteme und komplexe Arbeitsabläufe.
Die Phase Zwei des Projekts wird sich auf die Verbesserung der klinischen Abläufe von Boehringer und die Integration zusätzlicher regulatorischer Funktionsmodule konzentrieren. Die Implementierung zielt darauf ab, Datenprobleme zu lösen, Verzögerungen zu reduzieren und die Markteinführungszeit der Produkte des Unternehmens zu beschleunigen.
- Major contract implementation success with Boehringer Ingelheim, demonstrating Cognizant's capability in large-scale digital transformation
- Platform serves 15,000+ users, indicating significant contract value and recurring revenue potential
- Phase Two expansion confirms project success and potential for additional revenue
- None.
Insights
Cognizant has successfully delivered Phase One of a strategic digital transformation initiative for Boehringer Ingelheim, implementing an integrated cloud platform that consolidates over 20 legacy systems into a unified ecosystem. This marks a significant milestone in their partnership announced in 2023.
The "One Medicine Platform," powered by Veeva Development Cloud, streamlines pharmaceutical development processes across clinical, regulatory, and quality functions - directly impacting workflows for more than 15,000 users. As prime system integrator, Cognizant provided comprehensive services spanning program management, architecture design, integration, and validation.
Technology Integration Expert: The complexity of this implementation demonstrates Cognizant's advanced capabilities in life sciences technology integration. By replacing disparate systems with a unified platform, Cognizant addresses a critical industry challenge: fragmented data environments that slow drug development. The successful execution strengthens Cognizant's competitive position in the life sciences vertical, where digital transformation demands continue to accelerate. The multi-phase nature of this project suggests ongoing revenue potential as the relationship expands into Phase Two. While financial terms weren't disclosed, the project's scale indicates material value, with Cognizant demonstrating expertise in both technical implementation and organizational change management across multiple functions and user groups.
Life Sciences Consultant: This implementation addresses pharmaceutical R&D's most persistent challenge - siloed operations across development functions. By unifying clinical data, operations, regulatory affairs, and quality systems, Boehringer can significantly compress development timelines, potentially accelerating time-to-market for new therapies. The replacement of 20+ legacy systems also suggests substantial technical debt reduction and operational cost savings. For Cognizant, this project showcases their specialized knowledge in pharmaceutical development processes and validation requirements - a high-barrier entry point for technology providers. The client testimonial emphasizing operational efficiencies indicates measurable business impact, strengthening Cognizant's credentials for similar transformations across the pharmaceutical sector.
Powered by the Veeva Development Cloud, the system brings together previously disparate functions to streamline the medicinal development process and enhance operational efficiencies
Boehringer's "One Medicine Platform," replaces over 20 legacy platforms. The initiative unifies medicinal development processes and data sources into a connected ecosystem, with the aim of enhancing cross-functionality and operational efficiencies.
Cognizant, as the prime system integrator, began the Boehringer Ingelheim project by codeveloping a program roadmap, agile methodology, and implementation workflow. The overall scope of the project entails services such as program management, system architecture and design, training, integration, migration, testing and validation. Cognizant partnered closely with Syneos Health Consulting for business process engineering and with Veeva for configuration and system architecture and design.
In Phase One, Cognizant successfully supported implementation across clinical data, clinical operations, regulatory, and quality functions, enabling Boehringer Ingelheim's move onto the unified platform. This holistic approach is expected to streamline the workflows of 15,000+ users working in Clinical Development programs. In Phase Two, the collaborators look to further enhance Boehringer's clinical operations practice and integrate additional modules into its regulatory function.
"For years, Boehringer Ingelheim used multiple vendor systems which lacked the ability to communicate with each other, which led to complex workflows. The launch of our One Medicine Platform revolutionizes our medicinal development processes and takes our operational efficiencies to the next level," said Oliver Fink, Head Learning, Processes & Digitalization, Global Quality Medicine at Boehringer Ingelheim.
"We are pleased to achieve this program milestone in our collaboration with Boehringer Ingelheim," said Gagan Syal, Head of Life Sciences, EMEA & APAC, at Cognizant. "With this new system, Boehringer Ingelheim is expected to resolve data challenges and latencies and speed up the go-to-market of its products. Thanks to the close collaboration across our teams, we have been able to execute this project in record-time."
About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes, and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.
About Boehringer Ingelheim
https://www.boehringer-ingelheim.com/ Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com.
For more information, contact: GlobalPR@cognizant.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/boehringer-ingelheim-and-cognizant-announce-the-launch-of-a-unified-cloud-platform-to-bring-innovative-therapies-to-patients-faster-302397176.html
SOURCE Cognizant Technology Solutions
FAQ
What is the scope of Cognizant's (CTSH) One Medicine Platform implementation for Boehringer Ingelheim?
How many users will benefit from the new Cognizant (CTSH) platform at Boehringer Ingelheim?
What are the key partners involved in Cognizant's (CTSH) platform implementation?
What improvements does the Cognizant (CTSH) One Medicine Platform bring to Boehringer Ingelheim?
